Author Julie Kagawa Signs Major Multibook Deal for Harlequin Teen

Harlequin has announced the signing of New York Times and USA Today best-selling author Julie Kagawa to a major multibook deal for a new series (her third for Harlequin Teen), which will feature mythical creatures in a contemporary setting. Natashya Wilson, Harlequin Teen's executive editor, secured world rights and will edit the series. Laurie McLean, a senior agent at Larsen Pomada Literary Agents, brokered the deal.
Harlequin has announced the signing of New York Times and USA Today best-selling author Julie Kagawa to a major multibook deal for a new series (her third for Harlequin Teen), which will feature mythical creatures in a contemporary setting. Natashya Wilson, Harlequin Teen's executive editor, secured world rights and will edit the series. Laurie McLean, a senior agent at Larsen Pomada Literary Agents, brokered the deal. Julie KagawaKagawa is the author of two previous series—the best-selling “Iron Fey” and “Blood of Eden” series, which are in development for release as a film. The “Iron Fey” series has been published in more than 20 countries, and in 2011, it was a Teens Top Ten selection. The Immortal Rules is the first title in the dystopian “Blood of Eden” series and will be followed by the release of The Eternity Cure in May 2013. Movie rights to the “Blood of Eden” series have been optioned by Joni Sighvatsson of Palomar Pictures. Harlequin Teen plans to publish the first book in Kagawa’s new series in 2015. See more on Kagawa in her SummerTeen 2012 interview at SLJ.com.

Be the first reader to comment.

Comment Policy:
  • Be respectful, and do not attack the author, people mentioned in the article, or other commenters. Take on the idea, not the messenger.
  • Don't use obscene, profane, or vulgar language.
  • Stay on point. Comments that stray from the topic at hand may be deleted.
  • Comments may be republished in print, online, or other forms of media.
  • If you see something objectionable, please let us know. Once a comment has been flagged, a staff member will investigate.


RELATED 

ALREADY A SUBSCRIBER?

We are currently offering this content for free. Sign up now to activate your personal profile, where you can save articles for future viewing

ALREADY A SUBSCRIBER?